Evidence map›Paper›PMID 40948846›Full record

ArticleTranslational lung cancer research2025

Long-term survival with adaptive dual-targeted therapy in an epidermal growth factor receptor (

Xinyin Liu, Shidai Jin, Jun Li, Jiali Xu, Lei Song, Wen Gao, Jun Wang, Zhihong Zhang, Renhua Guo

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational lung cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Xinyin Liu *Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Shidai Jin *Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Jun Li *Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Jiali Xu *Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Lei SongDepartment of Hematology & Oncology, Taihu Hospital, Wuxi, China.
Wen GaoDepartment of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Jun WangDepartment of Thoracic Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Zhihong ZhangDepartment of Pathology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Renhua GuoDepartment of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Epidermal growth factor receptor-tyrosine kinase inhibitors ( Case Description: We report the case of a 65-year-old female patient with advanced lung adenocarcinoma (LUAD) who developed bone and adrenal gland metastases following treatment with gefitinib. Next-generation sequencing (NGS) of a biopsy specimen revealed the co-occurrence of Conclusions: We report the first case of a LUAD patient with

Indexed as

case reportcirculating tumor DNA (ctDNA)epidermal growth factor receptor (EGFR)Mesenchymal-epithelial transition amplification (MET amplification)non-small cell lung cancer (NSCLC)

Identifiers

PMID40948846
PMCPMC12432664

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.